ProShares UltraShort NASDAQ Biotechnology
11 hedge funds and large institutions have $4.82M invested in ProShares UltraShort NASDAQ Biotechnology in 2017 Q4 according to their latest regulatory filings, with 4 funds opening new positions, 3 increasing their positions, 2 reducing their positions, and 2 closing their positions.
157% more capital invested
Capital invested by funds: $1.88M → $4.82M (+$2.94M)
100% more first-time investments, than exits
New positions opened: 4 | Existing positions closed: 2
50% more repeat investments, than reductions
Existing positions increased: 3 | Existing positions reduced: 2
22% more funds holding
Funds holding: 9 → 11 (+2)
0.95% more ownership
Funds ownership: 0.53% → 1.49% (+0.95%)
0% more funds holding in top 10
Funds holding in top 10: 1 → 1 (0)
22% less call options, than puts
Call options by funds: $599K | Put options by funds: $772K
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Susquehanna International Group
Bala Cynwyd,
Pennsylvania
|
+$988K |
| 2 |
VF
Virtu Financial
New York
|
+$957K |
| 3 |
WP
WealthSource Partners
San Luis Obispo,
California
|
+$699K |
| 4 |
TRCT
Tower Research Capital (TRC)
New York
|
+$189K |
| 5 |
Citigroup
New York
|
+$45.3K |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
UBS Group
Zurich,
Switzerland
|
-$60.2K |
| 2 |
Morgan Stanley
New York
|
-$20.1K |
| 3 |
AG
Advisor Group
Phoenix,
Arizona
|
-$10K |
| 4 |
Simplex Trading
Chicago,
Illinois
|
-$2K |
| Name | Holding | Trade Value |
Shares Change |
Change in Stake |
|
|---|---|---|---|---|---|
|
VF
1
Virtu Financial
New York
| $1.64M | +$957K | +5,392 | +138% |
|
|
2
Susquehanna International Group
Bala Cynwyd,
Pennsylvania
| $982K | +$988K | +5,563 | New |
|
|
WP
3
WealthSource Partners
San Luis Obispo,
California
| $695K | +$699K | +3,938 | New |
|
|
HVC
4
Healthcare Value Capital
Woodcliff Lake,
New Jersey
| $551K | – | – | – |
|
|
TRCT
5
Tower Research Capital (TRC)
New York
| $527K | +$189K | +1,065 | +55% |
|
6
Citadel Advisors
Miami,
Florida
| $287K | +$16.7K | +94 | +6% |
|
|
7
Citigroup
New York
| $45K | +$45.3K | +255 | New |
|
8
Toronto Dominion Bank
Toronto, Ontario,
Ontario, Canada
| $31K | – | – | – |
|
|
9
Morgan Stanley
New York
| $25K | -$20.1K | -113 | -44% |
|
|
CA
10
Calton & Associates
Tampa,
Florida
| $22K | +$27.7K | +156 | New |
|
|
11
UBS Group
Zurich,
Switzerland
| $11K | -$60.2K | -339 | -85% |
|
|
AG
12
Advisor Group
Phoenix,
Arizona
| – | -$10K | -63 | Closed |
|
|
13
Simplex Trading
Chicago,
Illinois
| – | -$2K | -13 | Closed |
|
BIS Hedge Fund Activity: Q4 2017 in Review
11 of the 4,410 institutional investors tracked by Wall St. Rank reported a position in ProShares UltraShort NASDAQ Biotechnology (BIS) for Q4 2017, worth a combined $4.82M — up 157% from $1.88M a quarter earlier.
Buyers outnumbered sellers: 4 funds opened new BIS positions and 2 closed out — a net gain of 2 holders — while 3 added to existing stakes and 2 trimmed.
The largest buyer was Susquehanna International Group, opening a new position worth an estimated $988K. The largest seller was UBS Group, cutting an estimated $60.2K.
- 11 institutional investors held ProShares UltraShort NASDAQ Biotechnology (BIS) as of Q4 2017, up from 9 in Q3 2017.
- Funds reported $4.82M of ProShares UltraShort NASDAQ Biotechnology stock for Q4 2017, up 157% quarter-over-quarter.
- 4 funds opened new ProShares UltraShort NASDAQ Biotechnology positions in Q4 2017 and 2 closed out, a net change of +2 holders.
- The largest ProShares UltraShort NASDAQ Biotechnology buyer in Q4 2017 was Susquehanna International Group, an estimated $988K added.
- The largest ProShares UltraShort NASDAQ Biotechnology seller in Q4 2017 was UBS Group, an estimated $60.2K sold.
Based on aggregated 13F filings for Q4 2017.